Asmanex Twisthaler has been launched by Schering-Plough as therapy in the control and management of mild, moderate or severe persistent asthma in patients 12 years of age and older. It was launched in the United Kingdom in January and is expected to be launched in the other European Union(EU) markets, in the next few months. Asmanex Twisthaler, a dry powder inhaler, contains the orally inhaled corticosteroid mometasone furoate, which was discovered and developed by Schering-Plough Research Institute. The product employs a state-of-the-art, inhalation-driven device that does not use a propellant, thus eliminating the need for hand-breath coordination.
Asmanex Twisthaler represents a major new treatment option in helping asthma patients manage their disease and is a valuable addition to the therapies available to physicians for treating asthma, which is a serious and life-threatening disease. Richard Jay Kogan, President and CEO of Schering-Plough said that Asmanex, which is the first asthma therapy in international markets, represents an important advance for Schering-Plough and will significantly strengthen its respiratory portfolio, which includes Nasonex, an inhaled nasal steroid for allergies, and Clarinex, the once-daily non-sedating antihistamine. The Chairman, Hans-Jorg Kummer, added that the product's proven efficacy, convenient once-daily dosing and easy-to-use device would help patients better adhere to their dosing regimen and assist in achieving control of their asthma symptoms.